Quarterly report · Q2
7446.TEDINET S100TF5Q
Period2023-10-01 → 2024-03-31
Filed2024-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.6bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.4bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥276m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥532m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥302m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥552m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥314m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥552m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥211m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥367m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥373m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥19.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥18.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥17.8bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥12.1bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥11.7bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥226m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥185m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥54m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥335m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥288m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥83m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥96m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥46m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥233.86 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥174.52 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.21 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.9 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 38.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥8.3bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥8.3bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥7.1bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥7.1bn |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥16.6bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥16.6bn |
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥9.1bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥9.1bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥8.1bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥8.1bn |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥18.4bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥18.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 505
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 18445860000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | 9080592000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | 8054421000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1310845000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 18445860000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 18445860000 | JPY |
| Gross profit | Prior1YTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | 774507000 | JPY |
| Gross profit | Prior1YTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | 793791000 | JPY |
| Gross profit | Prior1YTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 187863000 | JPY |
| Gross profit | Prior1YTDDuration_ReportableSegmentsMember | 1756162000 | JPY |
| Gross profit | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Gross profit | Prior1YTDDuration | 1756162000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | 8335487000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | 7104352000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1178000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 16617840000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 16617840000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | 8335487000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | 7104352000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1178000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 16617840000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 16617840000 | JPY |
| Gross profit | CurrentYTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | 845894000 | JPY |
| Gross profit | CurrentYTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | 678680000 | JPY |
| Gross profit | CurrentYTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 146031000 | JPY |
| Gross profit | CurrentYTDDuration_ReportableSegmentsMember | 1670606000 | JPY |
| Gross profit | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Gross profit | CurrentYTDDuration | 1670606000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東北財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-05-15 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第73期第２四半期(自 2024年１月１日 至 2024年３月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)東北化学薬品株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |